How will we adjust the drop in PCR reimbursement drops

KRAS dropped 50%, BRAF dropped 90%, Stack Codes for Breast Cancer panels dropped up to 80%, everything in Molecular reimbursements just released today, it will drop our revenue up to 60% in this entire platforms. Good luck ladies and gentlemen, we are going down!

 

Bcr/abl, JAK, AML panels are dead, no more money...only pennies! We are dead!

 

Sorry for those who work there, but this couldn't happen to a better company! Name one offering of yours that docs and their patients can't go without...

 

fatass and company will guide us thru this mess

 

Aqua?

 

Fucked up too! Free bcr/abl now is truly free, it pays shit now anywaus!

 

Do you really believe Aqua sales have taken off in the 3 years since Genoptix acquired the exclusive rights?

 

Because once again they failed to market it appropriately. The thought should have been to give a revenue generator to the pathologists.

 

Actually, genoptix never counted on having to sell the benefit of their tests to the entities that hold the purse strings - the health insurance companies! It's like if Ford went out and developed a $40k muscle car that they solely marketed to teenagers; even if the teens loved it, Ford wouldn't make a dime if they can't convince the parents to pay for it!

And speaking as one of the contracting guys for a Blues plan, I can't say I'm too sad to see a worthless lab like Genoptix disappear from the scene. Glad to spend time dealing with labs whose tests are backed up with published, peer reviewed analytical validity, clinical validity, and clinical utility studies. Never gonna see that from you jokers...

 

Great point and good analogy. Genoptix and many other private labs are trying to sell unnecessary, jazzed-up tests that are not designed at all for patient well-being. They are just fattening up their bottom lines. Good to see the 'parents' tightening the purse strings.

 

Whatever happened to that Georgia Cancer study about patient outcomes that Leite touted so mightily (at least as mightily as a little guy who wears sweater vests that are tucked into his pants.)

 

Thanks for the kind words! Yep, for all that sucks about healthcare reform and the economy, it's forcing us payers to finally get smart about exactly what type of tests we pay for and how much. Nor reason to contract with a Genoptix if the peer-reviewed science shows the same testing (or better) offered by lower-cost labs is just as effective...

 

Novartis made a horrible investment or they didn't buy Genoptix for its market share and sales force. You make the call.

 

The market trend argues that Novartis made a horrible investment. But they weren't alone.

They pulled the trigger on the deal at the same time LabCorp threw a buttload of cash into the money pit that is Genzyme. Quest wrapped their loving arms around the ugly twin trolls that are Athena and (good Lord!) Berkeley Heart Labs.

 

Rumor has it Genoptix paid thousands of $ per month for those patient outcomes ---- hmmmmm

 

Bruce at GCS hosed us just like he did pharma. We were on a gravy train paying for bone marrows without patient consent. Then the managed care got wise and he internalized his work. Now they are back to square one since Northside purchased the paractice. Bruce is at Cardinal- left before the fines came from Medicare. Until these were clear Northside held up the buy.